Abstract 1066
Background
Ostomy patients (pts) can develop some complications treated by nurse enterostomista, such as skin alterations and early or late complications. Stomal complications have a varying incidence (from 25 to 35%). Neoplastic ostomy pts often undergo chemo (CT) and/or radiation therapy (RT), also in association, and they can show stomal lesions or complications with an important impact on their daily life. Stomal side effects induced by CT-RT represent an important problem for pts, who need for a competent and organized support in order to be able to cope with them. In the literature, few studies report the care and assistance to the stomized pts.The aim of this study was to detect precociously stomal complications in order to treat them early, improving pts quality of life, and to demonstrate that these complications are more frequent in pts treated with CT and/or RT.
Methods
From 11.2017 to 5.2018 60 cancer ostomy pts were surgically treated for different types of cancers at our institution. 29 out 60 have been also treated with CT and/or RT at Medical Oncology Dept. 73% were male and 27% female. We evaluated stomal complications and classified them according to SACS scale. Our aim was to demonstrate a higher percentage of stomal complications in pts CT and/or RT treated vs untreated pts.
Results
At a median follow-up of 4 months, 29 out 60 ostomy pts were treated with CT, 2 with CT-RT, the remaining 29 underwent follow-up. 15 out 29 pts (51%) treated with CT and/or RT showed stomal complications: 14 with SACS - L1 skin alterations (redness without loss of substance) and 1 with SACS-L2 lesion (with loss of substance). Patients undergoing follow-up didn’t have any stomal complications.
Conclusions
Despite the recognized limitations of our study (small sample size and short median follow-up) we can conclude that there is an increase of complications in ostomy pts treated with CT and/or RT vs untreated pts and that this problem occurs in over half of population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cristoforo Ferrero.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract